US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
pharma · Monocarboxylate Transporter 8 (MCT8) deficiency
Rare Thyroid Therapeutics
Rare Thyroid Therapeutics International AB
Rare Thyroid Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Stockholm, SE HQ
2017 Founded
1 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Stockholm, SE
- Founded
- 2017
- Employees
- 1
- Programs
- 2
- Drugs
- 6
- Patents
- 0
Rare Thyroid Therapeutics pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Rare Thyroid Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Rare Thyroid Therapeutics in public FDA and regional records.
-
Development asset linked to Rare Thyroid Therapeutics in public FDA and regional records.
-
Development asset linked to Rare Thyroid Therapeutics in public FDA and regional records.
-
tiratricol
Systemic hormonal preparations (H03)Systemic hormonal preparations (H03) compound in Rare Thyroid Therapeutics's portfolio. Molecular target: Thyroid hormone receptor.
- Target
- Thyroid hormone receptor
- Mechanism
- Thyroid hormone receptor agonist
-
Development asset linked to Rare Thyroid Therapeutics in public FDA and regional records.